Neoadjuvant chemotherapy with modified FOLFOXIRI for locally advanced rectal cancer to transform effectively EMVI and MRF from positive to negative: results of a long-term single center phase 2 clinical trial

PURPOSE: Chemoradiotherapy (CRT) remains the standard treatment for locally advanced rectal cancer (LARC). This phase 2 clinical trial was designed to evaluate the efficacy and safety of neoadjuvant triplet chemotherapy with mFOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin, and irinotecan) in L...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Wen, Zhou, Haitao, Jiang, Jun, Zhu, Yuelu, Zou, Shuangmei, Jiang, Liming, Tang, Yuan, Liang, Jianwei, Sun, Yongkun, Jiang, Zhichao, Qu, Wang, Li, Ying, Zhou, Aiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294487/
https://www.ncbi.nlm.nih.gov/pubmed/37370032
http://dx.doi.org/10.1186/s12885-023-11103-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294487/
https://www.ncbi.nlm.nih.gov/pubmed/37370032
http://dx.doi.org/10.1186/s12885-023-11103-x

Ejemplares similares